Progenies Receives FDA approval of first-and-only Azerda (iobenguane I 131) to treat Unresectable- LA/M Pheochromocytoma/Paraganglioma
Shots:
- AZEDRA radio therapeutic indicated to treat adult and pediatric patients ≥12yrs with iobenguane scan positive
- Has shown reduction rate in need of blood pressure medication and tumor size in patients for approved IV dose 555MBq/mL
- Approval was based on pivotal Ph 2 under SPA showing 17/68 (25%) ≥50% patients showed reduction in medication and tumor response of almost 53%
Ref: Progenics Pharmaceuticals | Image: LinkedIn
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
